Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 46708-494

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 46708-494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lurasidone-120 (Lurasidone 120mg)

This is a medication label for a drug called "Urasidone Hydrochloride". The usual dosage is one tablet of 120 mg daily. The manufacturer is not mentioned but there is a product code number.*

FDA Label Image

Lurasidone-20mg.jpg (Lurasidone 20mg)

FDA Label Image

Lurasidone-40mg.jpg (Lurasidone 40mg)

This appears to be a prescription label for a medication called Lurasidone Hydrochloride Tablets. The label includes dosage information and contact information for the pharmacy that dispensed the medication. It also mentions the importance of dispensing the accompanying Medication Guide to patients, although no details about the medication's indications or effects are provided.*

FDA Label Image

Lurasidone-60mg.jpg (Lurasidone 60mg)

FDA Label Image

Lurasidone-80mg.jpg (Lurasidone 80mg)

FDA Label Image

Lurasidone-figure-1.jpg (Lurasidone Figure 1)

Impact of other drugs on Lurasidone Pharmacokinetics (PK). The table shows the interacting drugs with Lurasidone, their PK fold change, and 90% CI. The strong CYP3A4 inhibitor, Ketoconazole at a dosage of 400 mg/day, has a significant impact on the Cmax and AUC of Lurasidone. Moderate CYP3A4 Inhibitor, Diltiazem at a dosage of 240 mg/day, shows an impact on Cmax. Besides, Strong CYP3A4 Inducer Rifampin at a dosage of 600 mg/day shows a change in Cmax and AUC. Lithium at a dosage of 600mg BID also shows changes in Cmax and AUC. However, no values are given in the table.*

FDA Label Image

Lurasidone-figure-2.jpg (Lurasidone Figure 2)

This appears to be a table showing PK (pharmacokinetic) changes in response to interacting drugs for various substances, including P-gp substrates such as Digoxin, CYPIA4 substrates like Midazolam, an oral contraceptive containing Ethinyl Estradiol and Norelgestromin, and Lithium. The table includes measurements for Crmax, Auc, and fold changes relative to the Interactive Drug Alone, as well as a 90% confidence interval.*

FDA Label Image

Lurasidone-figure-3.jpg (Lurasidone Figure 3)

FDA Label Image

Lurasidone-str.jpg (Lurasidone Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.